Maravai LifeSciences Holdings, Inc. (MAR.F)
| Previous close | 6.45 |
| Open | 6.40 |
| Bid | 6.35 x N/A |
| Ask | 6.40 x N/A |
| Day's range | 6.40 - 6.40 |
| 52-week range | 4.20 - 12.20 |
| Volume | |
| Avg. volume | 17 |
| Market cap | 1.604B |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center
SAN DIEGO, May 13, 2024--TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins Whiting School of Engineering will accelerate research and therapeutic development, leveraging TriLink’s leading RNA synthesis technology.
- GlobeNewswire
Maravai LifeSciences Announces May and June 2024 Investor Conference Schedule
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the months of May and June. On May 15, 2024, at 3:15 p.m. EST, Trey Martin, Chief Executive Officer and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the RBC Healthcare Conference in New York City, NY. On June 11, 2
- GlobeNewswire
Maravai LifeSciences Reports First Quarter 2024 Financial Results
Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific InnovationSAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2024, together with other business updates. Financial Highlights: Quarterly revenue of $64.2 million, Net loss of $(22.7) million, and Ad
